:: Library Catalog

Copertina

Salvato in:

Dettagli Bibliografici
Autori principali:	Takafumi Yanagisawa, Wataru Fukuokaya, Shingo Hatakeyama, Shintaro Narita, Katsuki Muramoto, Kouta Katsumi, Hidetsugu Takahashi, Fumihiko Urabe, Keiichiro Mori, Kojiro Tashiro, Kosuke Iwatani, Tatsuya Shimomura, Tomonori Habuchi, Takahiro Kimura
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	The Prostate
Accesso online:	https://onlinelibrary.wiley.com/doi/10.1002/pros.24813
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Assessment of Circulating Neuroendocrine Tumor Markers at Prostate Cancer Diagnosis: An Investigation of Prostate Cancer With Neuroendocrine Features
di: Tatsuya Shimomura, et al.
Pubblicazione: (2026)

Prognostic model for second progression‐free survival and overall survival in patients with high‐risk metastatic hormone‐sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy
di: Shintaro Narita, et al.
Pubblicazione: (2024)

Real‐World Comparative Study of Apalutamide Versus Bicalutamide in Combination With Androgen Deprivation Therapy for Metastatic Hormone‐Sensitive Prostate Cancer
di: Hidetsugu Takahashi, et al.
Pubblicazione: (2026)

Dose modification in enzalutamide and abiraterone plus prednisolone for castration‐resistant prostate cancer: A subanalysis from the ENABLE study for PCa
di: Nobumichi Tanaka, et al.
Pubblicazione: (2024)

Androgen‐Deprivation Therapy and Dietary Habits Influence the Gut Microbial Environment in Patients With High‐Risk Localized Prostate Cancer
di: Masanori Ishida, et al.
Pubblicazione: (2025)

The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line ARPI Therapy
di: Takeshi Tsutsumi, et al.
Pubblicazione: (2026)

Changes in the treatment landscape of metastatic hormone‐sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study
di: Fumihiko Urabe, et al.
Pubblicazione: (2024)

Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67
di: Fengnian Zhao, et al.
Pubblicazione: (2024)

Real‐world study: Impact of multidisciplinary management of apalutamide‐associated adverse events in prostate cancer
di: Julián Córdoba Sánchez, et al.
Pubblicazione: (2024)

PIK3/Akt/mTOR pathway alterations in metastatic castration‐sensitive prostate cancer
di: Philip Sutera, et al.
Pubblicazione: (2024)

Bellmunt risk score as a survival predictor in patients with metastatic castration‐resistant prostate cancer
di: Thomas Büttner, et al.
Pubblicazione: (2024)

Impact of presentation timing in metastatic hormone‐sensitive prostate cancer: Characterization of patients and identification of prognostic factors
di: Juliana Arenas Hoyos, et al.
Pubblicazione: (2024)

Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer patients
di: Tokiyoshi Tanegashima, et al.
Pubblicazione: (2024)

Real‐world prevalence of adverse events with first‐line systemic therapies among patients with metastatic castration‐sensitive prostate cancer
di: Umang Swami, et al.
Pubblicazione: (2024)

A panel‐based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration‐resistant prostate cancer
di: Daniel Boiarsky, et al.
Pubblicazione: (2024)

Reply to Letter to the Editor on “Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer patients”
di: Tokiyoshi Tanegashima, et al.
Pubblicazione: (2024)

A single‐center retrospective review of metastatic prostate cancer on PSMA position emission tomography/computed tomography: Beyond lymph nodes and bones
di: Gabriela N. C. De Jesus, et al.
Pubblicazione: (2024)

Clinical validation of circulating GDF15/MIC‐1 as a marker of response to docetaxel and survival in men with metastatic castration‐resistant prostate cancer
di: Kate L. Mahon, et al.
Pubblicazione: (2024)

Comprehensive Genomic Profiling Testing for Castration‐Resistant Prostate Cancer in Advanced Elderly Patients: A Single‐Center Retrospective Cohort Study
di: Takafumi Fukushima, et al.
Pubblicazione: (2025)

Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real‐world setting of metastatic hormone‐sensitive prostate cancer patients
di: Mike Wenzel, et al.
Pubblicazione: (2024)

Molecular analysis of archival diagnostic prostate cancer biopsies identifies genomic similarities in cases with progression post‐radiotherapy, and those with de novo metastatic disease
di: Philip Vincent Charlton, et al.
Pubblicazione: (2024)

Survival of patients with lymph node versus bone versus visceral metastases according to CHAARTED/LATITUDE criteria in the era of intensified combination therapies for metastatic hormone‐sensitive prostate cancer
di: Mike Wenzel, et al.
Pubblicazione: (2024)

Deep PSA response and extended time‐to‐nadir as robust predictors of survival in Asian patients with de novo metastatic hormone‐sensitive prostate cancer receiving upfront intensified treatment
di: Chris H.‐M. Wong, et al.
Pubblicazione: (2024)

The Effects of the Blood‐Based S2,3PSA% Test on Prostate Cancer Screening: A Novel Approach to Reduce the Need for MRI and Unnecessary Biopsies
di: Hikari Miura, et al.
Pubblicazione: (2025)

Efficacy, Safety, and Cost‐Effectiveness of Reduced versus Full Initial Doses of Androgen Receptor Signaling Inhibitors in Non‐Metastatic Castration‐Resistant Prostate Cancer: A Multicenter Retrospective Study
di: Himawari Asanuma, et al.
Pubblicazione: (2026)

Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration‐Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate
di: Mitsuhisa Nishimoto, et al.
Pubblicazione: (2025)

Comparative antiproliferation of human prostate cancer cells by ethanolic extracts of two groups of Brazilian propolis
di: Cleber Silveira MORAES
Pubblicazione: (2010)

Other‐cause mortality in incidental prostate cancer
di: Francesco Di Bello, et al.
Pubblicazione: (2024)

Diagnostic Performance of the Novel Biomarker S2,3PSA Density for Prostate Biopsy Optimization in Prostate Imaging Reporting and Data System 3–5 Lesions
di: Takanori Tokunaga, et al.
Pubblicazione: (2025)

Combining Prostate‐Specific Antigen Density With PI‐RADS to Improve the Detection of Clinically Significant Prostate Cancer at MRI/TRUS Fusion‐Targeted Re‐Biopsy
di: Yuto Ono, et al.
Pubblicazione: (2025)

The Clinical Significance of Gallium‐68 PSMA‐11 PET‐Derived SUVmax in the Management of Metastatic Hormone‐Sensitive Prostate Cancer
di: Cevat İlteriş Kıkılı, et al.
Pubblicazione: (2026)

Prostate Cancer Cells With the AR‐Low and EMT‐High Phenotype Are Vulnerable to NAD+ Synthesis Inhibitors
di: Hyun‐Kyung Ko, et al.
Pubblicazione: (2025)

Cover Image: Volume 86 Issue 7
di: Amod Sharma, et al.
Pubblicazione: (2026)

External validation of the Memorial Sloan Kettering Cancer Center preoperative nomogram predicting lymph node invasion in a cohort of high‐grade prostate cancer patients
di: Nawar Touma, et al.
Pubblicazione: (2024)

Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate
di: Eric V. Li, et al.
Pubblicazione: (2024)

Discovering the Prostate: Notes on History and Historiography
di: Diederik F. Janssen
Pubblicazione: (2025)

Comparative Evaluation of Detection Rates for Clinically Significant Prostate Cancer Using MRI‐Targeted Biopsy Alone Versus in Combination With Systematic Biopsies: Development of a Risk‐Stratification Scoring System
di: Toshifumi Takahashi, et al.
Pubblicazione: (2024)

USPSTF Recommendation Against PSA Screening vs. Stage and Cancer‐Specific Mortality in Localized Prostate Cancer
di: Fabian Falkenbach, et al.
Pubblicazione: (2025)

Insights and Limitations in Evaluating Testosterone Recovery With LHRH Antagonists and Agonists
di: Satı Coşkun Yazgan, et al.
Pubblicazione: (2026)

Real‐World Comparison of Triplet Versus Doublet Therapy in Japanese Patients With High‐Volume Metastatic Hormone‐Sensitive Prostate Cancer: A Propensity‐Weighted Analysis From the YUSHIMA Registry and Exploratory Bayesian Evidence Synthesis
di: Yosuke Yasuda, et al.
Pubblicazione: (2026)